Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Executive Vice President | July 29, 2016 | July 29, 2016 |
| AbbVie Inc.ABBV · Entity 2800 | Director | May 08, 2026 | May 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date July 29, 2016 · Filed July 29, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 395,819 |
Ending reported balance
After 2016-07-29 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2016-07-29 · Exercise / conversion · Acquired 56,000 · Balance 438,682 Row 2 · 2016-07-29 · Tax withholding · Disposed 42,863 · Balance 395,819 |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.25 · Expires 2017-02-15 | Direct | 0 |
Reported balance
After 2016-07-29 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2016-07-29 · Exercise / conversion · Disposed 56,000 · Balance 0 F6: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. |
| Common shares without par valueSEC Table I · non-derivative | IndirectProfit Sharing Trust | 1,130 |
Reported balance
Holding disclosure · report date 2016-07-29 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,130 F1: Balance in the Abbott Laboratories Stock Retirement Trust as of July 28, 2016. |
| Common shares without par valueSEC Table I · non-derivative | IndirectAnnette Newton-Freyman 1994 Trust | 4,000 |
Reported balance
Holding disclosure · report date 2016-07-29 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 4,000 F2: Held in the Annette Newton-Freyman 1994 Trust. The reporting person's spouse is trustee of the trust. The trust is revocable by his spouse. The reporting person disclaims beneficial ownership of these securities. |
| Common shares without par valueSEC Table I · non-derivative | IndirectAnnette Newton-Freyman 2012 Irrevocable Trust | 76,000 |
Reported balance
Holding disclosure · report date 2016-07-29 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 76,000 F3: Held in the Annette Newton-Freyman 2012 Irrevocable Trust. The reporting person is trustee of the trust. The trust is irrevocable. The reporting person disclaims beneficial ownership of these securities. |
| Common shares without par valueSEC Table I · non-derivative | IndirectThomas C. Freyman 2012 Irrevocable Trust | 76,000 |
Reported balance
Holding disclosure · report date 2016-07-29 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 76,000 F4: Held in the Thomas C. Freyman 2012 Irrevocable Trust. The reporting person's spouse is trustee of the trust. The trust is irrevocable. |
| Common shares without par valueSEC Table I · non-derivative | IndirectBy spouse as trustee for son | 1,941 |
Reported balance
Holding disclosure · report date 2016-07-29 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 1,941 F5: These shares are held in an irrevocable trust for the benefit of the reporting person's son. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities. |
| Common shares without par valueSEC Table I · non-derivative | IndirectBy spouse as trustee for son | 1,941 |
Reported balance
Holding disclosure · report date 2016-07-29 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 1,941 F5: These shares are held in an irrevocable trust for the benefit of the reporting person's son. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities. |
Filing footnotes · ownership attribution and instrument terms
F1: Balance in the Abbott Laboratories Stock Retirement Trust as of July 28, 2016.
F2: Held in the Annette Newton-Freyman 1994 Trust. The reporting person's spouse is trustee of the trust. The trust is revocable by his spouse. The reporting person disclaims beneficial ownership of these securities.
F3: Held in the Annette Newton-Freyman 2012 Irrevocable Trust. The reporting person is trustee of the trust. The trust is irrevocable. The reporting person disclaims beneficial ownership of these securities.
F4: Held in the Thomas C. Freyman 2012 Irrevocable Trust. The reporting person's spouse is trustee of the trust. The trust is irrevocable.
F5: These shares are held in an irrevocable trust for the benefit of the reporting person's son. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities.
F6: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.
AbbVie Inc.
Report date May 08, 2026 · Filed May 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 par valueSEC Table I · non-derivative | Direct | 127,869 |
Reported balance
After 2026-05-08 transaction · row 1
1 source rowRow 1 · 2026-05-08 · Grant · Acquired 1,118 · Balance 127,869 F1: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). |
| Common Stock, $0.01 par valueSEC Table I · non-derivative | IndirectBy spouse in trust | 4,000 |
Reported balance
Holding disclosure · report date 2026-05-08 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 4,000 F2: The reporting person's spouse is the trustee of the trust. The trust is revocable by his spouse. The reporting person disclaims beneficial ownership of these securities. |
| Common Stock, $0.01 par valueSEC Table I · non-derivative | IndirectBy spouse in trust for son | 1,941 |
Reported balance
Holding disclosure · report date 2026-05-08 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,941 F3: Shares are held in an irrevocable trust for the benefit of the reporting person's son. The reporting person's spouse is the trustee of the trust. The reporting person disclaims beneficial ownership of these securities. |
| Common Stock, $0.01 par valueSEC Table I · non-derivative | IndirectBy spouse in trust for son | 1,941 |
Reported balance
Holding disclosure · report date 2026-05-08 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 1,941 F3: Shares are held in an irrevocable trust for the benefit of the reporting person's son. The reporting person's spouse is the trustee of the trust. The reporting person disclaims beneficial ownership of these securities. |
Filing footnotes · ownership attribution and instrument terms
F1: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).
F2: The reporting person's spouse is the trustee of the trust. The trust is revocable by his spouse. The reporting person disclaims beneficial ownership of these securities.
F3: Shares are held in an irrevocable trust for the benefit of the reporting person's son. The reporting person's spouse is the trustee of the trust. The reporting person disclaims beneficial ownership of these securities.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Allergan plc
Report date May 08, 2020 · Filed May 12, 2020
Section 16 reporting ended · disclosed 2020-05-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares, par value $0.0001SEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-05-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-05-08 · Disposition to issuer · Disposed 2,983 · Balance 0 F1: Reflects the disposition of ordinary shares ("Allergan Shares") of Allergan plc ("Allergan") as contemplated by the Transaction Agreement dated as of June 25, 2019 among AbbVie Inc. ("AbbVie"), Venice Subsidiary, LLC ("Acquirer Sub") and Allergan (the "Transaction Agreement"), pursuant to which Acquirer Sub acquired Allergan pursuant to a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act of 2014 and the capital reduction under Sections 84 and 85 of the Act (the "Scheme"). In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Share was converted into $120.30 in cash and 0.8660 of a newly issued share of AbbVie common stock, par value $0.01 per share. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of ordinary shares ("Allergan Shares") of Allergan plc ("Allergan") as contemplated by the Transaction Agreement dated as of June 25, 2019 among AbbVie Inc. ("AbbVie"), Venice Subsidiary, LLC ("Acquirer Sub") and Allergan (the "Transaction Agreement"), pursuant to which Acquirer Sub acquired Allergan pursuant to a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act of 2014 and the capital reduction under Sections 84 and 85 of the Act (the "Scheme"). In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Share was converted into $120.30 in cash and 0.8660 of a newly issued share of AbbVie common stock, par value $0.01 per share.
HANGER, INC.
Report date October 03, 2022 · Filed October 04, 2022
Section 16 reporting ended · disclosed 2022-10-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 1
1 source rowRow 1 · 2022-10-03 · Disposition to issuer · Disposed 43,561 · Balance 0 F1: Represents shares of issuer's common stock and restricted stock units relating to such common stock that were disposed of in connection with the merger of Hero Merger Sub, Inc. with and into issuer (the "Merger") pursuant to the Agreement and Plan of Merger, dated as of July 21, 2022, by and among issuer, Hero Parent, Inc. and Hero Merger Sub, Inc. (the "Merger Agreement"). At the effective time of the Merger, each issued and outstanding share of issuer's common stock (subject to certain exceptions described in the Merger Agreement) and each restricted stock unit were canceled and converted into the right to receive $18.75 in cash. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of issuer's common stock and restricted stock units relating to such common stock that were disposed of in connection with the merger of Hero Merger Sub, Inc. with and into issuer (the "Merger") pursuant to the Agreement and Plan of Merger, dated as of July 21, 2022, by and among issuer, Hero Parent, Inc. and Hero Merger Sub, Inc. (the "Merger Agreement"). At the effective time of the Merger, each issued and outstanding share of issuer's common stock (subject to certain exceptions described in the Merger Agreement) and each restricted stock unit were canceled and converted into the right to receive $18.75 in cash.
TENNECO INC
Report date November 17, 2022 · Filed November 21, 2022
Section 16 reporting ended · disclosed 2022-11-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-11-17 transaction · row 1
1 source rowRow 1 · 2022-11-17 · Disposition to issuer · Disposed 93,892 · Balance 0 F1: Reflects disposition upon completion of the merger (the "Merger") of Pegasus Merger Co. ("Merger Sub"), a wholly owned subsidiary of Pegasus Holdings III, LLC ("Parent"), with and into the Issuer, effective November 17, 2022. Pursuant to the Agreement and Plan of Merger, dated as of February 22, 2022, by and among the Issuer, Parent and Merger Sub, upon completion of the Merger, each outstanding share of the Issuer's Class A Common Stock was converted into the right to receive $20.00 per share in cash. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition upon completion of the merger (the "Merger") of Pegasus Merger Co. ("Merger Sub"), a wholly owned subsidiary of Pegasus Holdings III, LLC ("Parent"), with and into the Issuer, effective November 17, 2022. Pursuant to the Agreement and Plan of Merger, dated as of February 22, 2022, by and among the Issuer, Parent and Merger Sub, upon completion of the Merger, each outstanding share of the Issuer's Class A Common Stock was converted into the right to receive $20.00 per share in cash.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 08, 2026 Filed May 12, 2026 21:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 1,118 | $0.00 | $0.00 |
DisclosureSEC source: 0001239126-26-000002 · form4-05122026_050509.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,869 F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| May 09, 2025 Filed May 13, 2025 21:05 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 1,203 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-012802 · form4-05132025_050522.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,751 F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| May 03, 2024 Filed May 7, 2024 22:30 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 1,322 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-012524 · form4-05072024_060515.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,548 F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| May 05, 2023 Filed May 9, 2023 21:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 1,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-007666 · form4-05092023_050507.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,226 F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| November 17, 2022 Filed Nov 21, 2022 16:33 UTC | TENNECO INC TEN · Entity 11746 | Disposition to issuerClass A Common Stock | 93,892 | $20.00 | $1,877,840.00 |
DisclosureSEC source: 0001209191-22-058159 · doc4.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Reflects disposition upon completion of the merger (the "Merger") of Pegasus Merger Co. ("Merger Sub"), a wholly owned subsidiary of Pegasus Holdings III, LLC ("Parent"), with and into the Issuer, effective November 17, 2022. Pursuant to the Agreement and Plan of Merger, dated as of February 22, 2022, by and among the Issuer, Parent and Merger Sub, upon completion of the Merger, each outstanding share of the Issuer's Class A Common Stock was converted into the right to receive $20.00 per share in cash. F1 · price: Reflects disposition upon completion of the merger (the "Merger") of Pegasus Merger Co. ("Merger Sub"), a wholly owned subsidiary of Pegasus Holdings III, LLC ("Parent"), with and into the Issuer, effective November 17, 2022. Pursuant to the Agreement and Plan of Merger, dated as of February 22, 2022, by and among the Issuer, Parent and Merger Sub, upon completion of the Merger, each outstanding share of the Issuer's Class A Common Stock was converted into the right to receive $20.00 per share in cash. Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 17:16 UTC | HANGER, INC. HNGR · Entity 14115 | Disposition to issuerCommon Stock | 43,561 | $18.75 | $816,768.75 |
DisclosureSEC source: 0001567619-22-018181 · doc1.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · acquired: Represents shares of issuer's common stock and restricted stock units relating to such common stock that were disposed of in connection with the merger of Hero Merger Sub, Inc. with and into issuer (the "Merger") pursuant to the Agreement and Plan of Merger, dated as of July 21, 2022, by and among issuer, Hero Parent, Inc. and Hero Merger Sub, Inc. (the "Merger Agreement"). At the effective time of the Merger, each issued and outstanding share of issuer's common stock (subject to certain exceptions described in the Merger Agreement) and each restricted stock unit were canceled and converted into the right to receive $18.75 in cash. Read SEC document |
| June 02, 2022 Filed Jun 3, 2022 16:41 UTC | HANGER, INC. HNGR · Entity 14115 | GrantCommon Stock | 9,911 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-012294 · doc1.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,561 F1 · shares: Consists of shares of restricted stock granted under the Company's 2022 Omnibus Incentive Plan (the "Plan"), which vest 100% on June 2, 2023, subject to certain provisions of the Plan. .. Read SEC document |
| May 06, 2022 Filed May 9, 2022 21:11 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 1,421 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-002927 · edgar.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,776 F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 18:21 UTC | TENNECO INC TEN · Entity 11746 | GrantClass A Common Stock | 15,110 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006528 · doc4.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,892 F1 · kind: Reflects stock granted to the Reporting Person pursuant to Rule 16b-3. Read SEC document |
| May 26, 2021 Filed May 27, 2021 17:22 UTC | HANGER, INC. HNGR · Entity 14115 | GrantCommon Stock | 5,484 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-011291 · doc1.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,650 F1 · shares: Consists of shares of restricted stock granted under the Company's 2019 Omnibus Incentive Plan (the "Plan"), which vest 100% on May 26, 2022, subject to certain provisions of the Plan. .. Read SEC document |
| May 07, 2021 Filed May 11, 2021 21:05 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 1,681 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-005201 · edgar.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,355 F1 · shares: These are restricted stock units awarded under the AbbVie 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 16:56 UTC | TENNECO INC TEN · Entity 11746 | GrantClass A Common Stock | 10,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-007769 · doc4.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,782 F1 · kind: Reflects stock granted to the Reporting Person pursuant to Rule 16b-3. Read SEC document |
| August 07, 2020 Filed Aug 7, 2020 21:17 UTC | TENNECO INC TEN · Entity 11746 | PurchaseClass A Common Stock | 30,000 | $7.70 | $231,000.00 |
DisclosureSEC source: 0001209191-20-045818 · doc4.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,932 F1 · price: The shares purchased by the Reporting Person and reported herein were purchased at a range of between $7.665 and $7.795 per share. The purchase price represents the weighted average purchase price for the reported transaction and has been rounded to the nearest cent. Read SEC document |
| May 20, 2020 Filed May 21, 2020 16:51 UTC | HANGER, INC. HNGR · Entity 14115 | GrantCommon Stock | 8,178 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-010932 · doc1.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,166 F1 · shares: Consists of shares of restricted stock granted under the Company's 2019 Omnibus Incentive Plan (the "Plan"), which vest 100% on May 20, 2021, subject to certain provisions of the Plan. .. Read SEC document |
| May 08, 2020 Filed May 12, 2020 01:46 UTC | Allergan plc AGN · Entity 149298 | Disposition to issuerOrdinary Shares, par value $0.0001 | 2,983 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-012750 · doc4.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · balance_after: Reflects the disposition of ordinary shares ("Allergan Shares") of Allergan plc ("Allergan") as contemplated by the Transaction Agreement dated as of June 25, 2019 among AbbVie Inc. ("AbbVie"), Venice Subsidiary, LLC ("Acquirer Sub") and Allergan (the "Transaction Agreement"), pursuant to which Acquirer Sub acquired Allergan pursuant to a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act of 2014 and the capital reduction under Sections 84 and 85 of the Act (the "Scheme"). In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Share was converted into $120.30 in cash and 0.8660 of a newly issued share of AbbVie common stock, par value $0.01 per share. Read SEC document |
| May 08, 2020 Filed May 12, 2020 21:54 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 2,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-20-005836 · edgar.xml · nonDerivative · entry 2 FREYMAN THOMAS C · CIK 0001239126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,675 F2 · kind: These are restricted stock units awarded under the AbbVie 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). F2 · price: These are restricted stock units awarded under the AbbVie 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| May 08, 2020 Filed May 12, 2020 21:54 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 2,583 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-20-005836 · edgar.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,342 F1 · price: Received in exchange for 2,983 shares of Allergan plc common stock in connection with its acquisition by AbbVie Inc. Allergan shareholders received 0.8660 AbbVie shares for each Allergan share (based on the closing price of AbbVie's common stock of $84.22 on May 7, 2020). Read SEC document |
| May 08, 2020 Filed May 22, 2020 21:47 UTC Amendment | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 2,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-20-006518 · edgar.xml · nonDerivative · entry 2 FREYMAN THOMAS C · CIK 0001239126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,675 F2 · price: These are restricted stock units awarded under the AbbVie 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| May 08, 2020 Filed May 22, 2020 21:47 UTC Amendment | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 2,583 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-20-006518 · edgar.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,342 F1 · price: Received in exchange for 2,983 shares of Allergan plc common stock in connection with its acquisition by AbbVie Inc. Allergan shareholders received 0.8660 AbbVie shares for each Allergan share (based on the closing price of AbbVie's common stock of $84.22 on May 7, 2020). Read SEC document |
| May 01, 2020 Filed May 5, 2020 00:58 UTC | Allergan plc AGN · Entity 149298 | Tax withholdingOrdinary Shares, par value $0.0001 | 2,064 | $189.74 | $391,623.36 |
DisclosureSEC source: 0001179110-20-005447 · edgar.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,983 Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 19:52 UTC | TENNECO INC TEN · Entity 11746 | GrantClass A Common Stock | 12,208 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007312 · doc4.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,932 F1 · kind: Reflects stock granted to the Reporting Person pursuant to Rule 16b-3. Read SEC document |
| May 23, 2019 Filed May 24, 2019 17:48 UTC | HANGER, INC. HNGR · Entity 14115 | GrantCommon Stock | 6,969 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-012146 · doc1.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,988 F1 · shares: Consists of shares of restricted stock granted under the Company's 2019 Omnibus Incentive Plan (the "Plan"), which vest 100% on May 23, 2020, subject to certain provisions of the Plan. .. Read SEC document |
| May 02, 2019 Filed May 2, 2019 20:44 UTC | Allergan plc AGN · Entity 149298 | GrantOrdinary Shares, par value $0.0001 | 2,064 | $145.33 | $299,961.12 |
DisclosureSEC source: 0001179110-19-005413 · edgar.xml · nonDerivative · entry 2 FREYMAN THOMAS C · CIK 0001239126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,974 F2 · shares: These restricted stock units shall vest 100% on the earlier of (i) the day before the 2020 Annual General Meeting of Shareholders and (ii) May 1, 2020. F1 · balance_after: Includes restricted stock units issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document |
| April 30, 2019 Filed May 2, 2019 20:44 UTC | Allergan plc AGN · Entity 149298 | Tax withholdingOrdinary Shares, par value $0.0001 | 748 | $147.00 | $109,956.00 |
DisclosureSEC source: 0001179110-19-005413 · edgar.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,910 F1 · balance_after: Includes restricted stock units issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document |
| February 05, 2019 Filed Feb 7, 2019 17:08 UTC | TENNECO INC TEN · Entity 11746 | GrantClass A Common Stock | 3,459 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008124 · doc4.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,724 F1 · kind: Reflects stock granted to the Reporting Person pursuant to Rule 16b-3. Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 21:07 UTC | Allergan plc AGN · Entity 149298 | PurchaseOrdinary Shares, par value $0.0001 | 1,100 | $190.69 | $209,759.00 |
DisclosureSEC source: 0001179110-18-011085 · edgar.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,658 F1 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document |
| August 09, 2018 Filed Aug 10, 2018 11:26 UTC | TENNECO INC TEN · Entity 11746 | PurchaseCommon Stock | 5,000 | $44.49 | $222,450.00 |
DisclosureSEC source: 0001209191-18-046150 · doc4.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,265 F1 · price: The Common Stock purchased by the Reporting Person and reported herein were purchased at a range of between $44.33 and $44.58 per share. The purchase price represents the weighted average purchase price for the reported transaction and has been rounded to the nearest cent. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 19:01 UTC | Allergan plc AGN · Entity 149298 | GrantOrdinary Shares, par value $0.0001 | 1,558 | $170.23 | $265,218.34 |
DisclosureSEC source: 0001179110-18-008592 · edgar.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,558 F1 · shares: These restricted stock units shall vest 100% on the earlier of (i) the day before the 2019 Annual General Meeting of Shareholders and (ii) May 2, 2019. F2 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document |
| May 16, 2018 Filed May 17, 2018 13:55 UTC | HANGER, INC. HNGR · Entity 14115 | GrantCommon Stock | 7,672 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-024371 · doc1.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,019 F1 · shares: Consists of shares of restricted stock granted under the Company's 2016 Omnibus Incentive Plan (the "Plan"), which vest 100% on May 16, 2019, subject to certain provisions of the Plan. Read SEC document |
| February 07, 2018 Filed Feb 9, 2018 12:36 UTC | TENNECO INC TEN · Entity 11746 | GrantCommon Stock | 2,180 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-008715 · doc4.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,265 F1 · kind: Reflects stock granted to the Reporting Person pursuant to Rule 16b-3. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 16:21 UTC | HANGER, INC. HGR · Entity 14115 | GrantCommon Stock | 5,347 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-043225 · doc1.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,347 F1 · shares: Consists of shares of restricted stock granted under the Company's 2016 Omnibus Incentive Plan (the "Plan"), which vest 100% on November 15, 2018, subject to certain provisions of the Plan. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 14:36 UTC | TENNECO INC TEN · Entity 11746 | GrantCommon Stock | 1,756 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-007505 · doc4.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,085 F1 · kind: Reflects stock granted to the Reporting Person pursuant to Rule 16b-3. Read SEC document |
| July 29, 2016 Filed Jul 29, 2016 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 56,000 | $0.00 Strike: $25.25 | $0.00 |
DisclosureSEC source: 0001179110-16-028022 · edgar.xml · derivative · entry 9 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 56,000 shares Expires 2017-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| July 29, 2016 Filed Jul 29, 2016 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 42,863 | $44.45 | $1,905,260.35 |
DisclosureSEC source: 0001179110-16-028022 · edgar.xml · nonDerivative · entry 2 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 395,819 Read SEC document |
| July 29, 2016 Filed Jul 29, 2016 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 56,000 | $25.25 | $1,413,781.60 |
DisclosureSEC source: 0001179110-16-028022 · edgar.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 438,682 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 29, 2016 Filed Mar 2, 2016 22:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 19,908 | $39.52 | $786,764.16 |
DisclosureSEC source: 0001179110-16-020710 · edgar.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 382,682 Read SEC document |
| February 19, 2016 Filed Feb 23, 2016 23:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 485,159 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001179110-16-019924 · edgar.xml · derivative · entry 8 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 485,159 Underlying: Common shares · 485,159 shares Expires 2026-02-18 F7 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 161,720 on 02/19/2017, 161,719 on 02/19/2018, and 161,720 on 02/19/2019. Read SEC document |
| February 19, 2016 Filed Feb 23, 2016 23:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 55,338 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-019924 · edgar.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 402,590 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 27, 2015 Filed Mar 3, 2015 22:17 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 22,797 | $47.61 | $1,085,365.17 |
DisclosureSEC source: 0001179110-15-004046 · edgar.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 347,252 Read SEC document |
| February 20, 2015 Filed Feb 24, 2015 23:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 284,857 | $0.00 Strike: $47.00 | $0.00 |
DisclosureSEC source: 0001179110-15-003340 · edgar.xml · derivative · entry 8 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,857 Underlying: Common shares · 284,857 shares Expires 2025-02-19 F7 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 94,953 on 2/20/16, 94,952 on 2/20/17, and 94,952 on 2/20/18. Read SEC document |
| February 20, 2015 Filed Feb 24, 2015 23:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 40,425 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-15-003340 · edgar.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 370,049 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| July 21, 2014 Filed Jul 22, 2014 21:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 56,000 | $0.00 Strike: $25.25 | $0.00 |
DisclosureSEC source: 0001179110-14-011914 · edgar.xml · derivative · entry 11 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,000 Underlying: Common shares · 56,000 shares Expires 2017-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| July 21, 2014 Filed Jul 22, 2014 21:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 23,000 | $0.00 Strike: $21.22 | $0.00 |
DisclosureSEC source: 0001179110-14-011914 · edgar.xml · derivative · entry 10 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 23,000 shares Expires 2016-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| July 21, 2014 Filed Jul 22, 2014 21:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 60,702 | $42.73 | $2,593,796.46 |
DisclosureSEC source: 0001179110-14-011914 · edgar.xml · nonDerivative · entry 3 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 329,624 Read SEC document |
| July 21, 2014 Filed Jul 22, 2014 21:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 56,000 | $25.25 | $1,413,781.60 |
DisclosureSEC source: 0001179110-14-011914 · edgar.xml · nonDerivative · entry 2 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 390,326 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 21, 2014 Filed Jul 22, 2014 21:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 23,000 | $21.22 | $488,046.20 |
DisclosureSEC source: 0001179110-14-011914 · edgar.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 334,326 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2014 Filed Mar 4, 2014 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,984 | $39.10 | $116,686.34 |
DisclosureSEC source: 0001179110-14-004303 · edgar.xml · nonDerivative · entry 2 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 311,326 Read SEC document |
| February 28, 2014 Filed Mar 4, 2014 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 27,660 | $39.79 | $1,100,591.40 |
DisclosureSEC source: 0001179110-14-004303 · edgar.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,310 Read SEC document |
| February 21, 2014 Filed Feb 25, 2014 22:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 200,477 | $0.00 Strike: $39.12 | $0.00 |
DisclosureSEC source: 0001179110-14-003608 · edgar.xml · derivative · entry 8 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,477 Underlying: Common shares · 200,477 shares Expires 2024-02-20 F7 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 66,826 on 2/21/2015, 66,825 on 2/21/2016, and 66,826 on 2/21/2017. Read SEC document |
| February 21, 2014 Filed Feb 25, 2014 22:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 32,746 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-14-003608 · edgar.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 341,970 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.